Table 2 Use of second generation antipsychotics, mood stabilizers and SSRI/SNRIsâ€
From: A Canadian naturalistic study of a community-based cohort treated for bipolar disorder
Medication* | Baseline | One Month | ||
|---|---|---|---|---|
| Â | Olanzapine (n= 287) | Other (n= 209) | Olanzapine (n= 270) | Other (n= 200) |
SGA + Mood Stabilizer | 97 (34%) | 55 (26%) | 90 (33%) | 60 (30%) |
SGA Alone | 87 (30%) | 42 (20%) | 75 (28%) | 37 (19%) |
SGA + SSRI/SNRI | 51 (18%) | 23 (11%) | 43 (16%) | 30 (15%) |
SGA + SSRI/SNRI + Mood Stabilizer | 34 (12%) | 24 (11%) | 39 (14%) | 27 (14%) |
Mood Stabilizer Alone | 8 (3%) | 38 (18%) | 7 (3%) | 28 (14%) |
Mood Stabilizer + SSRI/SNRI | 5 (2%) | 13 (6%) | 6 (2%) | 8 (4%) |
SSRI/SNRI Alone | 3 (1%) | 8 (4%) | 3 (1%) | 3 (2%) |